69 related articles for article (PubMed ID: 21873168)
21. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury.
Heller T; Hennecke M; Baumann U; Gessner JE; zu Vilsendorf AM; Baensch M; Boulay F; Kola A; Klos A; Bautsch W; Köhl J
J Immunol; 1999 Jul; 163(2):985-94. PubMed ID: 10395696
[TBL] [Abstract][Full Text] [Related]
22. A novel interpretation of immune redundancy and duality in reperfusion injury with important implications for intervention in ischaemic disease.
Thrane AS; Skehan JD; Thrane PS
Med Hypotheses; 2007; 68(6):1363-70. PubMed ID: 17169498
[TBL] [Abstract][Full Text] [Related]
23. A novel TLR4-binding peptide that inhibits LPS-induced activation of NF-kappaB and in vivo toxicity.
Sugiyama K; Muroi M; Tanamoto K
Eur J Pharmacol; 2008 Oct; 594(1-3):152-6. PubMed ID: 18700140
[TBL] [Abstract][Full Text] [Related]
24. Agonist-dependent phosphorylation of N-formylpeptide and activation peptide from the fifth component of C (C5a) chemoattractant receptors in differentiated HL60 cells.
Tardif M; Mery L; Brouchon L; Boulay F
J Immunol; 1993 Apr; 150(8 Pt 1):3534-45. PubMed ID: 8468487
[TBL] [Abstract][Full Text] [Related]
25. Extracellular high mobility group box-1 inhibits R5 and X4 HIV-1 strains replication in mononuclear phagocytes without induction of chemokines and cytokines.
Cassetta L; Fortunato O; Adduce L; Rizzi C; Hering J; Rovere-Querini P; Bianchi ME; Alfano M; Poli G
AIDS; 2009 Mar; 23(5):567-77. PubMed ID: 19194273
[TBL] [Abstract][Full Text] [Related]
26. HMGB1 modulates inflammatory responses in LPS-activated macrophages.
El Gazzar M
Inflamm Res; 2007 Apr; 56(4):162-7. PubMed ID: 17522814
[TBL] [Abstract][Full Text] [Related]
27. Modeling molecular mechanisms of binding of the anaphylatoxin C5a to the C5a receptor.
Nikiforovich GV; Marshall GR; Baranski TJ
Biochemistry; 2008 Mar; 47(10):3117-30. PubMed ID: 18275159
[TBL] [Abstract][Full Text] [Related]
28. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a.
Wong AK; Finch AM; Pierens GK; Craik DJ; Taylor SM; Fairlie DP
J Med Chem; 1998 Aug; 41(18):3417-25. PubMed ID: 9719594
[TBL] [Abstract][Full Text] [Related]
29. Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator.
Erlandsson Harris H; Andersson U
Eur J Immunol; 2004 Jun; 34(6):1503-12. PubMed ID: 15162419
[TBL] [Abstract][Full Text] [Related]
30. Therapeutical Administration of Peptide Pep19-2.5 and Ibuprofen Reduces Inflammation and Prevents Lethal Sepsis.
Heinbockel L; Marwitz S; Barcena Varela S; Ferrer-Espada R; Reiling N; Goldmann T; Gutsmann T; Mier W; Schürholz T; Drömann D; Brandenburg K; Martinez de Tejada G
PLoS One; 2015; 10(7):e0133291. PubMed ID: 26197109
[TBL] [Abstract][Full Text] [Related]
31. Inactivation of C5a anaphylatoxin by a peptide that is complementary to a region of C5a.
Fujita E; Farkas I; Campbell W; Baranyi L; Okada H; Okada N
J Immunol; 2004 May; 172(10):6382-7. PubMed ID: 15128829
[TBL] [Abstract][Full Text] [Related]
32. The enigma of sepsis.
Riedemann NC; Guo RF; Ward PA
J Clin Invest; 2003 Aug; 112(4):460-7. PubMed ID: 12925683
[TBL] [Abstract][Full Text] [Related]
33. [C5A receptor: a new potential therapeutic target for immune-mediated glomerulonephritis].
Cannone M
G Ital Nefrol; 2012; 29(6):645. PubMed ID: 23229657
[No Abstract] [Full Text] [Related]
34. High mobility group box 1 (HMGB1).
Yang H; Tracey KJ
Crit Care Med; 2005 Dec; 33(12 Suppl):S472-4. PubMed ID: 16340425
[No Abstract] [Full Text] [Related]
35. Peptide aptamers: powerful new tools for molecular medicine.
Hoppe-Seyler F; Butz K
J Mol Med (Berl); 2000; 78(8):426-30. PubMed ID: 11097111
[TBL] [Abstract][Full Text] [Related]
36. Sense-antisense (complementary) peptide interactions and the proteomic code; potential opportunities in biology and pharmaceutical science.
Miller AD
Expert Opin Biol Ther; 2015 Feb; 15(2):245-67. PubMed ID: 25584818
[TBL] [Abstract][Full Text] [Related]
37. Interaction of Human C5a with the Major Peptide Fragments of C5aR1: Direct Evidence in Support of "Two-Site" Binding Paradigm.
Das A; Behera LM; Rana S
ACS Omega; 2021 Sep; 6(35):22876-22887. PubMed ID: 34514259
[TBL] [Abstract][Full Text] [Related]
38. Treatment of Paraquat-Induced Lung Injury With an Anti-C5a Antibody: Potential Clinical Application.
Sun S; Jiang Y; Wang R; Liu C; Liu X; Song N; Guo Y; Guo R; Du L; Jiang S; Li Y; Qiu Z; Zhao G; Zhou Y
Crit Care Med; 2018 May; 46(5):e419-e425. PubMed ID: 29293144
[TBL] [Abstract][Full Text] [Related]
39. C5a inhibitor protects against ischemia/reperfusion injury in rat small intestine.
Tuboly E; Futakuchi M; Varga G; Érces D; Tőkés T; Mészáros A; Kaszaki J; Suzui M; Imai M; Okada A; Okada N; Boros M; Okada H
Microbiol Immunol; 2016 Jan; 60(1):35-46. PubMed ID: 26576826
[TBL] [Abstract][Full Text] [Related]
40. Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys.
Sun S; Zhao G; Liu C; Fan W; Zhou X; Zeng L; Guo Y; Kou Z; Yu H; Li J; Wang R; Li Y; Schneider C; Habel M; Riedemann NC; Du L; Jiang S; Guo R; Zhou Y
Clin Infect Dis; 2015 Feb; 60(4):586-95. PubMed ID: 25433014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
